Bank of New York Mellon Corp raised its position in GlaxoSmithKline PLC (NYSE:GSK) by 1.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,062,964 shares of the pharmaceutical company’s stock after buying an additional 86,277 shares during the period. Bank of New York Mellon Corp’s holdings in GlaxoSmithKline PLC were worth $261,495,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. M&R Capital Management Inc. purchased a new position in shares of GlaxoSmithKline PLC during the second quarter worth about $109,000. Quadrant Capital Group LLC increased its position in shares of GlaxoSmithKline PLC by 6.4% in the second quarter. Quadrant Capital Group LLC now owns 2,725 shares of the pharmaceutical company’s stock worth $111,000 after buying an additional 163 shares during the period. Thrivent Financial for Lutherans increased its position in shares of GlaxoSmithKline PLC by 3.8% in the second quarter. Thrivent Financial for Lutherans now owns 2,651 shares of the pharmaceutical company’s stock worth $115,000 after buying an additional 96 shares during the period. SevenBridge Financial Group LLC purchased a new position in shares of GlaxoSmithKline PLC during the second quarter worth about $116,000. Finally, Physicians Financial Services Inc. increased its position in shares of GlaxoSmithKline PLC by 25.9% in the third quarter. Physicians Financial Services Inc. now owns 2,691 shares of the pharmaceutical company’s stock worth $116,000 after buying an additional 553 shares during the period. 8.67% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

GlaxoSmithKline PLC (NYSE:GSK) opened at 38.27 on Wednesday. GlaxoSmithKline PLC has a 52-week low of $37.65 and a 52-week high of $45.58. The company’s 50-day moving average is $39.97 and its 200 day moving average is $42.36. The company has a market cap of $93.11 billion, a price-to-earnings ratio of 251.78 and a beta of 0.93.

The company also recently disclosed a dividend, which will be paid on Thursday, January 12th. Shareholders of record on Friday, November 4th will be given a dividend of $0.459 per share. The ex-dividend date is Wednesday, November 2nd. GlaxoSmithKline PLC’s dividend payout ratio is currently 1,533.33%.

COPYRIGHT VIOLATION WARNING: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this report can be viewed at http://www.dailypolitical.com/2016/11/30/glaxosmithkline-plc-gsk-shares-bought-by-bank-of-new-york-mellon-corp.html.

A number of research analysts recently issued reports on GSK shares. Citigroup Inc. reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Friday, September 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, October 25th. Piper Jaffray Cos. started coverage on shares of GlaxoSmithKline PLC in a research report on Friday, September 23rd. They set an “overweight” rating on the stock. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, August 2nd. Finally, Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a research report on Tuesday, September 27th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. GlaxoSmithKline PLC currently has an average rating of “Hold” and a consensus price target of $48.20.

In related news, major shareholder Plc Glaxosmithkline purchased 66,500 shares of the stock in a transaction dated Monday, October 24th. The stock was purchased at an average price of $14.00 per share, with a total value of $931,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 10.00% of the company’s stock.

About GlaxoSmithKline PLC

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.